Switch maintenance tyrosine kinase inhibitors in EGFR mutation positive metastatic non-squamous NSCLC: experience from the real world
GJO-Gulf Journal of Oncology [The]. 2016; (22): 6-10
in English
| IMEMR
| ID: emr-184372
ABSTRACT
Background:
Induction pemetrexed platin doublet is the standard of care in locally advanced and metastatic non squamous NSCLC. Maintenance TKI has been successfully explored to sustain benefit achieved after induction therapy especially in EGFR mutation positive NSCLC. The aim of this study is to evaluate outcomes with maintenance TKI in EGFR mutation positive metastatic non squamous NSCLC after induction pemetrexed-platin doublet. The objective is to calculate progression freesurvival rate, overall survival rate and factors affectingoutcomes:
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Gulf J. Oncol.
Year:
2016
Similar
MEDLINE
...
LILACS
LIS